FT516 for Non-Hodgkin's Lymphoma
This trial is testing a new cancer drug, FT516, to see if it is safe and effective when used alone or with other drugs to treat AML or B-cell lymphoma.
- Non-Hodgkin's Lymphoma
- Acute Myeloid Leukemia
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
To what extent is the patient population engaged in this medical study?
"Indeed, the trial is still recruiting. According to clinicaltrials.gov, it was originally posted on October 4th 2019 and most recently updated on July 25th 2022. Currently 234 volunteers are needed across 7 different locations for this study."
Has the FDA sanctioned FT516 for use yet?
"The safety of FT516 has been given a rating of 1, owing to the limited amount of clinical data available regarding its efficacy and potential side effects. This is an early phase trial."
What are the known outcomes of prior FT516 studies?
"As of now, 1241 FT516 studies are ongoing with 238 in Phase 3. Most these trials take place in Philadelphia; however, there exist 41188 other sites conducting clinical research on this drug."
Is enrollment still open for participation in this research project?
"Indeed, according to the data accessible on clinicaltrials.gov this experiment is at present open for enrollment. Originally posted in October 4th 2019, it was recently refreshed on July 25th 2022. Approximately 234 volunteers must be recruited from 7 distinct sites."
How many healthcare locations are currently conducting this experiment in the state?
"Seven different clinical centres are taking part in this trial, with Seattle's Swedish Cancer Institute, Phoenix's Mayo Clinic, and Dallas' UT Southwestern being some of the leading sites. Additionally, four other locations have been recruited to take part."